Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp63 | Developmental & Protein Endocrinology | ECE2017

Does the loss of RAD52 in PC contribute to resistance to antiandrogen therapy?

Alfaqih Mahmoud A. , Chang Ching yi , Norris John , McDonnell Donald P.

Recent statistics indicate that prostate cancer (PC) is the most frequent cancer in men worldwide and is the leading cause of cancer death in men above 50 years of age. The Androgen receptor (AR), a member of the superfamily of nuclear hormone receptors, plays a well-established role in the development and progression of the disease. PC localized to the prostate is commonly treated with surgical removal of the gland and is often associated with a favorable outcome. However, me...